To evaluate pharmacokinetic properties and drug interactions between D326 and D337 co-administered groups, the CKD-828 alone and the total co-administered groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
D326, D337 or CKD-828 for 9 days
D326, D337 or CKD-828 for 9 days
D326, D337 or CKD-828 for 9 days
Asan Medical Center, University of Ulsan
Seoul, South Korea
RECRUITINGCmax(Maximum plasma concentration of the drug at steady state)
PK parameters of D326, D337 and CKD-828
Time frame: at Day 9
AUCtau(area under the plasma concentration-time curve for a dosing interval at steady state)
PK parameters of D326, D337 and CKD-828
Time frame: at Day 9
Tmax(Time to maximum plasma concentration at steady state)
PK parameters of D326, D337 and CKD-828
Time frame: at Day 9
t1/2(Terminal elimination half-life)
PK parameters of D326, D337 and CKD-828
Time frame: at Day 9
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
D326, D337 or CKD-828 for 9 days
D326, D337 or CKD-828 for 9 days
D326, D337 or CKD-828 for 9 days